BACKGROUND In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data...

Disorders of the endocrine system including hormone hyperfunction and hypofunction have multiple effects on cardiovascular system. However, in clinical practice, there are many cases of delayed or overlooked diagnosis of underlying endocrine dysfunction in patients presenting chest pain or other cardiac symptoms. Herein, we report three cases of endocrine hyperfunction presenting as coronary sp...

The SARS-CoV-2 virus that caused the 2019 new coronavirus infection (COVID-19) pandemic has posed an unprecedented challenge to global health system and scientific community. As of this literature review, claimed more than 6 million lives, 500 people worldwide have already been infected with SARS-CoV-2. In addition basic, pulmonary manifestations disease, as well severe, life-threatening compli...

The pattern of HLA-DR antigens was studied in a group of 66 patients with Addisonian pernicious anaemia, comprising a subgroup of 18 patients with associated endocrine disease and a subgroup of 48 patients with no associated endocrine disease. Compared with a control group of 120 subjects all 66 patients showed an increase in HLA-DR2 and DR4 and a decrease in DR3 (p less than 0.02). Significant...

In 31 patients with multiple sclerosis (MS) the endocrine functions of the hypothalamus, the pituitary and several peripheral endocrine glands were assessed with a combined pituitary test; 3/31 patients had an endocrine disease: one primary hypothyroidism, one primary amenorrhea and one primary male hypogonadism. We found no patient with endocrine disease of the hypothalamus, the pituitary or t...

1. Chairman’s Introduction 616 R.W. Blamey 2. For which tumour types should endocrine therapy be restricted? 617 R. Nicholson, W. Miller, P.E. Lonning 3. Endocrine therapy in primary breast cancer 619 L. Rutqvist, R. Jakesz, A. Goldhirsch, M. Baum 4. Endocrine therapy in primary breast cancer 624 C. Rose, F. Boccardo, M. Piccart, B.J.K. Thürlimann, K. Holli 5. Other indications for endocrine th...